1.Comparison of the sodium content of Korean soup-based dishes prepared at home, restaurants, and schools in Seoul
Yanghee PARK ; Jihyun YOON ; Sang-Jin CHUNG
Journal of Nutrition and Health 2020;53(6):663-675
Purpose:
The aim of this study was to measure the sodium content of the solid and liquid components of soup-based dishes (SBD) including Korean soup, stew, noodle/dumplings, and watery kimchi and to compare the sodium content in the dishes from home, schools, and restaurants in Seoul.
Methods:
The dishes were divided into 3 groups, namely home, restaurant and school food.We separated the dishes into solid and liquid to measure the weight, salinity, and sodium content. The sodium content of the dishes was analyzed using inductively coupled plasma atomic emission spectrometry.
Results:
The proportion of sodium content in the liquid component of SBD were 65.2%– 66.7% in soup, 49.8%–61.2% in stew, 48.7%–56.7% in noodle/dumpling, and 43.7%–73.2% in watery kimchi. The sodium content per 100 g of the whole dishes of the same kind from the schools was significantly lower than that from the restaurants and home. However, there was no significant difference in sodium content per 100 g of whole dishes between the restaurants and home. The sodium content per 100 g of liquid in the same kind of dishes from the schools was significantly lower than those from the restaurants and home, and that from home was significantly lower than from the restaurants.
Conclusion
The sodium content of the liquid in SBD accounted for at least about half of the total sodium content of the whole dishes. It is important to establish a separate database with the sodium content in the solid and liquid portions of SBD and to evaluate how much liquid and/or solid would be consumed to estimate individual sodium intake more accurately.Also, it should be noted that the sodium content varies with the origin of the dishes, whether dishes were from home, restaurants, or schools.
2.In Vitro Adenosine Triphosphate Based Chemotherapy Response Assay in Gastric Cancer.
Seulkee PARK ; Yanghee WOO ; Hogeun KIM ; Yong Chan LEE ; Sungho CHOI ; Woo Jin HYUNG ; Sung Hoon NOH
Journal of Gastric Cancer 2010;10(4):155-161
PURPOSE: The purpose of this study was to investigate the reliability and the clinical applicability of the adenosine-triphosphate-based chemotherapy response assay (ATP-CRA) as a method of determining in vitro chemosensitivity in patients with gastric cancer. MATERIALS AND METHODS: A total of 243 gastric cancer tissue samples were obtained from gastrectomies performed between February 2007 and January 2010. We evaluated the effectiveness of the ATP-CRA assay in determining the chemosensitivity of gastric cancer specimens using eleven chemotherapeutic agents - etoposide, doxorubicin, epirubicin, mytomicin, 5-fluorouracil, oxaliplatin, irinotecan, docetaxel, paclitaxel, methotraxate, and cisplatin - for chemosensitivity studies using ATP-CRA. We assessed the failure rate, the cell death rate, and the chemosensitivity index. RESULTS: The failure rate of ATP-CRA was 1.6% (4/243). The mean coefficient of variation for triplicate ATP measurements was 6.5%. Etoposide showed the highest cell death rate (35.9%) while methotrexate showed the lowest (16.6%). The most active chemotherapeutic agent was etoposide, which most frequently ranked highest in the chemosensitivity test: 31.9% (51/160). Oxaliplatin was more active against early gastric cancers than advanced gastric cancers, whereas docetaxel was more active against advanced cancers. The lymph node negative group showed a significantly higher cell death rate than the lymph node positive group when treated with doxorubicin, epirubicin, and mitomycin. CONCLUSIONS: ATP-CRA is a stable and clinically applicable in vitro chemosensitivity test with a low failure rate. The clinical usefulness of ATP-CRA should be evaluated by prospective studies comparing the regimen guided by ATP-CRA with an empirical regimen.
Adenosine
;
Adenosine Triphosphate
;
Camptothecin
;
Cell Death
;
Cisplatin
;
Doxorubicin
;
Epirubicin
;
Etoposide
;
Fluorouracil
;
Gastrectomy
;
Humans
;
Lymph Nodes
;
Methotrexate
;
Organoplatinum Compounds
;
Paclitaxel
;
Polyphosphates
;
Stomach Neoplasms
;
Taxoids
3.In Vitro Adenosine Triphosphate Based Chemotherapy Response Assay in Gastric Cancer.
Seulkee PARK ; Yanghee WOO ; Hogeun KIM ; Yong Chan LEE ; Sungho CHOI ; Woo Jin HYUNG ; Sung Hoon NOH
Journal of Gastric Cancer 2010;10(4):155-161
PURPOSE: The purpose of this study was to investigate the reliability and the clinical applicability of the adenosine-triphosphate-based chemotherapy response assay (ATP-CRA) as a method of determining in vitro chemosensitivity in patients with gastric cancer. MATERIALS AND METHODS: A total of 243 gastric cancer tissue samples were obtained from gastrectomies performed between February 2007 and January 2010. We evaluated the effectiveness of the ATP-CRA assay in determining the chemosensitivity of gastric cancer specimens using eleven chemotherapeutic agents - etoposide, doxorubicin, epirubicin, mytomicin, 5-fluorouracil, oxaliplatin, irinotecan, docetaxel, paclitaxel, methotraxate, and cisplatin - for chemosensitivity studies using ATP-CRA. We assessed the failure rate, the cell death rate, and the chemosensitivity index. RESULTS: The failure rate of ATP-CRA was 1.6% (4/243). The mean coefficient of variation for triplicate ATP measurements was 6.5%. Etoposide showed the highest cell death rate (35.9%) while methotrexate showed the lowest (16.6%). The most active chemotherapeutic agent was etoposide, which most frequently ranked highest in the chemosensitivity test: 31.9% (51/160). Oxaliplatin was more active against early gastric cancers than advanced gastric cancers, whereas docetaxel was more active against advanced cancers. The lymph node negative group showed a significantly higher cell death rate than the lymph node positive group when treated with doxorubicin, epirubicin, and mitomycin. CONCLUSIONS: ATP-CRA is a stable and clinically applicable in vitro chemosensitivity test with a low failure rate. The clinical usefulness of ATP-CRA should be evaluated by prospective studies comparing the regimen guided by ATP-CRA with an empirical regimen.
Adenosine
;
Adenosine Triphosphate
;
Camptothecin
;
Cell Death
;
Cisplatin
;
Doxorubicin
;
Epirubicin
;
Etoposide
;
Fluorouracil
;
Gastrectomy
;
Humans
;
Lymph Nodes
;
Methotrexate
;
Organoplatinum Compounds
;
Paclitaxel
;
Polyphosphates
;
Stomach Neoplasms
;
Taxoids